Skip to content
lifestyle.socialsinsider.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
RIGEL PHARMACEUTICALS, INC.
Rigel Announces Closing of Licensing Agreement for VEPPANU™ (vepdegestrant)
June 16, 2026
Rigel to Present at the Jefferies Global Healthcare Conference
May 31, 2026
Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress
May 30, 2026
Rigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference
May 29, 2026
Rigel Reports First Quarter 2026 Financial Results
May 28, 2026
Rigel Announces Conference Call and Webcast to Report First Quarter 2026 Financial Results
May 26, 2026
Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology
May 22, 2026
Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer
May 12, 2026
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update
February 24, 2026
Rigel Appoints Michael P. Miller to the Board of Directors
February 11, 2026
1
2
Next Page
→